A clinical trial involving vasoactive intestinal peptide was updated on June 30, 2026. The study, titled "Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)," is registered under NCT04788277. Its current status is listed as active, not recruiting. No phase designation was provided in the trial record. The trial focuses on detecting prostate cancer through voided urine samples, according to its title. No results or outcome data have been reported in this update. The status change indicates that the study is ongoing but is no longer enrolling new participants at this time. Further details about the trial's design, objectives, or methodology were not included in the available event data. Readers seeking more information can consult the official trial registration for complete documentation. This update reflects only the status as recorded on the specified date and does not include any interim findings or conclusions. For additional context on vasoactive intestinal peptide, readers can refer to the compound overview.
Trial Update: VIP-Related "Prostate VPAC" Study Now Active, Not Recruiting
See the full vasoactive intestinal peptide overview
Source: https://clinicaltrials.gov/study/NCT04788277